País: Canadá
Idioma: francés
Fuente: Health Canada
Pémétrexed (Hémipentahydrate de pémétrexed disodique)
MARCAN PHARMACEUTICALS INC
L01BA04
PEMETREXED
500MG
Poudre pour solution
Pémétrexed (Hémipentahydrate de pémétrexed disodique) 500MG
Intraveineuse
50ML
Prescription
ANTINEOPLASTIC AGENTS
Numéro de groupe d'ingrédients actifs (GIA) :0150104001; AHFS:
APPROUVÉ
2018-02-02
Page 1 of 61 PRODUCT MONOGRAPH PR PEMETREXED DISODIUM FOR INJECTION Mfr. Std. 500 mg pemetrexed per vial (as pemetrexed disodium hemipentahydrate) Sterile Lyophilized Powder Antineoplastic Agent Marcan Pharmaceuticals Inc. Date of Preparation: 2 Gurdwara Road, Suite #112 August 24, 2018 Ottawa, ON, K2E 1A2 Control # 218069 Page 2 of 61 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS.................................................................................................. 20 DOSAGE AND ADMINISTRATION.............................................................................. 19 OVERDOSAGE ................................................................................................................ 24 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 25 STORAGE AND STABILITY ......................................................................................... 27 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 27 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 27 PART II: SCIENTIFIC INFORMATION............................................................................... 28 PHARMACEUTICAL INFORMATION ......................................................................... 28 CLINICAL TRIALS ...................................... Leer el documento completo